Drug Database
Back to search

Poland· PL-100200010

Sufentanil Chiesi

A sufentanil product containing sufentanilum, registered in Poland by Chiesi Pharmaceuticals GmbH. The same ATC class is registered in 11 of our 19 countries.

ATC N01AH03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSufentanil ChiesiATCN01AH03REGISTER NO.PL-100200010PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sufentanilumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sufentanil is registered in 11 of 19 countries.

Countries holding a registration under ATC N01AH03 (sufentanil), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search sufentanil products by name

Sufentanil · ATC N01AH03

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Sufentanilum
Manufacturer
Chiesi Pharmaceuticals GmbH
Country
Poland (PL)
ATC code
N01AH03
ATC class
Sufentanil
Defined daily dose
30 mcg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991024611
  • gtin
    05909991024628

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

216 interactions on record for sufentanil.

Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sufentanil against other medicinesHow interaction checks work

Sufentanil · interactions on record

216 records

  • 20 severe
  • 158 moderate
  • 38 info

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sufentanil in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sufentanil products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Sufenta, Sufentanil Hameln
  • Belgium · Sufenta, Sufenta Forte
  • Cyprus · Sofentil
  • Czechia · Sontilen, Sufenta
  • Germany · Sufenta, Sufenta Epidural
  • Denmark · Sofentil, Sufenta
  • Spain · Safentil, Secufen
  • Finland · Sufenta, Sufenta Forte
  • France · Sufenta, Sufentanil Renaudin
  • United Kingdom (Northern Ireland) · Dzuveo
  • Croatia · Sofentil, Sufentanil Altamedics
  • Hungary · Sufentanil Hameln, Sufentanil Torrex
  • Iceland · Dzuveo, Sufenta
  • Italy · Disufen, Sufentanil Hameln
  • Liechtenstein · Dzuveo, Sufenta
  • Luxembourg · Sufenta, Sufenta Forte
  • Latvia · Sontilen
  • Malta · Sofentil
  • Netherlands · Narcomed, Sufenta
  • Norway · Dzuveo, Sufenta
  • Portugal · Sontilen, Sufenta
  • Romania · Sofentil
  • Sweden · Sufenta, Sufentanil Hameln
  • Slovenia · Sufentanil Hameln
  • Slovakia · Sofentil, Sufentanil Chiesi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4e807e8d-888f-4ea9-bd21-a435f12dd4a2
GET /v1/drugs/4e807e8d-888f-4ea9-bd21-a435f12dd4a2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "50 mcg/ml, (250 mcg/5 ml, 1 mg/20 ml)",
  "packaging": "05909991024611 ¦ Lz ¦ 22284\n5 amp. 5 ml\n05909991024628 ¦ Lz ¦ 22285\n5 amp. 20 ml",
  "substance": "Sufentanili citras 0,375 mg/5 ml + Sufentanili citras 1,5 mg/20 ml",
  "common_name": "Sufentanilum",
  "pl_product_id": "100200010",
  "pozwolenie_nr": "10246",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about sufentanil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console